Potential Positives. Independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease patients proceed without ...

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's disease candidate from its Brainshuttle programme, a technology designed to ...

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid ...